Clinical Significance of Para-Aortic Lymph Node Dissection for Advanced or Metastatic Colorectal Cancer in the Current Era of Modern Chemotherapy

被引:25
作者
Arimoto, Atsuki [1 ]
Uehara, Keisuke [1 ]
Kato, Takehiro [1 ]
Nakamura, Hayato [1 ]
Kamiya, Tadahiro [1 ]
Nagino, Masato [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan
关键词
Colorectal cancer; Para-aortic lymph node metastasis; Lymph node dissection; Modern chemotherapy; RESECTABLE LIVER METASTASES; PLUS BEVACIZUMAB; OPEN-LABEL; CETUXIMAB; OXALIPLATIN; LEUCOVORIN; RECURRENCE; RESECTION; SURGERY; FOLFOX4;
D O I
10.1159/000439547
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Surgical resection is not generally indicated for para-aortic lymph node (PALN) metastasis from colorectal cancer. However, the clinical significance of PALN dissection (PALND) in the current era of modern chemotherapy has not been fully discussed. Methods: Between November 2006 and February 2013, 14 patients underwent PALND for colorectal cancer and were proven as having pathological PALN metastasis. The median follow-up was 33.2 months. Results: Primary location was the right-colon in 2 patients, and the left-colon or rectum in 12 patients. The timing of metastasis was metachronous in 5 patients and synchronous in 9 patients. Eleven patients (79%) received perioperative aggressive modern chemotherapy. Neoadjuvant chemotherapy with targeted drugs was introduced in 9 patients (64%) and 6 patients received adjuvant chemotherapy. Recurrence after PALND occurred in 12 patients (86%). The most common site was the lung in 6 patients (43%). The 1- and 3-year disease-free survivals were 39.3 and 7.9%, respectively. The 3-year overall survival were 41.2%. Conclusion: The recurrence rate after PALND for strictly selected patients was quite high even in the current era of modern chemotherapy. However, some patients achieved long-term survival or could be cured. Therefore, we should re-evaluate the efficacy of PALND in a larger prospective study. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:439 / 444
页数:6
相关论文
共 19 条
[11]  
Machiki Y, 1990, Nihon Geka Gakkai Zasshi, V91, P844
[12]   Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma [J].
Min, Byung Soh ;
Kim, Nam Kyu ;
Sohn, Seung Kook ;
Cho, Chang Hwan ;
Lee, Kang Young ;
Baik, Seung Hyuk .
JOURNAL OF SURGICAL ONCOLOGY, 2008, 97 (02) :136-140
[13]   Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial [J].
Nordlinger, Bernard ;
Sorbye, Halfdan ;
Glimelius, Bengt ;
Poston, Graeme J. ;
Schlag, Peter M. ;
Rougier, Philippe ;
Bechstein, Wolf O. ;
Primrose, John N. ;
Euan, T. Walpole ;
Finch-Jones, Meg ;
Jaeck, Daniel ;
Mirza, Darius ;
Parks, Rowan W. ;
Collette, Laurence ;
Praet, Michel ;
Bethe, Ullrich ;
Van Cutsem, Eric ;
Scheithauer, Werner ;
Gruenberger, Thomas .
LANCET, 2008, 371 (9617) :1007-1016
[14]   Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial [J].
Nordlinger, Bernard ;
Sorbye, Halfdan ;
Glimelius, Bengt ;
Poston, Graeme J. ;
Schlag, Peter M. ;
Rougier, Philippe ;
Bechstein, Wolf O. ;
Primrose, John N. ;
Walpole, Euan T. ;
Finch-Jones, Meg ;
Jaeck, Daniel ;
Mirza, Darius ;
Parks, Rowan W. ;
Mauer, Murielle ;
Tanis, Erik ;
Van Cutsem, Eric ;
Scheithauer, Werner ;
Gruenberger, Thomas .
LANCET ONCOLOGY, 2013, 14 (12) :1208-1215
[15]   Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial [J].
Primrose, John ;
Falk, Stephen ;
Finch-Jones, Meg ;
Valle, Juan ;
O'Reilly, Derek ;
Siriwardena, Ajith ;
Hornbuckle, Joanne ;
Peterson, Mark ;
Rees, Myrddin ;
Iveson, Tim ;
Hickish, Tamas ;
Butler, Rachel ;
Stanton, Louise ;
Dixon, Elizabeth ;
Little, Louisa ;
Bowers, Megan ;
Pugh, Sian ;
Garden, O. James ;
Cunningham, David ;
Maughan, Tim ;
Bridgewater, John .
LANCET ONCOLOGY, 2014, 15 (06) :601-611
[16]   Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma [J].
Shibata, D ;
Paty, PB ;
Guillem, JG ;
Wong, WD ;
Cohen, AM .
DISEASES OF THE COLON & RECTUM, 2002, 45 (06) :795-801
[17]  
Sobin L., 2002, International Union against Cancer. TNM classification of malignant tumours, V6th
[18]   Japanese Society for Cancer of the Colon and Rectum (JS']JSCCR) guidelines 2010 for the treatment of colorectal cancer [J].
Watanabe, Toshiaki ;
Itabashi, Michio ;
Shimada, Yasuhiro ;
Tanaka, Shinji ;
Ito, Yoshinori ;
Ajioka, Yoichi ;
Hamaguchi, Tetsuya ;
Hyodo, Ichinosuke ;
Igarashi, Masahiro ;
Ishida, Hideyuki ;
Ishiguro, Megumi ;
Kanemitsu, Yukihide ;
Kokudo, Norihiro ;
Muro, Kei ;
Ochiai, Atsushi ;
Oguchi, Masahiko ;
Ohkura, Yasuo ;
Saito, Yutaka ;
Sakai, Yoshiharu ;
Ueno, Hideki ;
Yoshino, Takayuki ;
Fujimori, Takahiro ;
Koinuma, Nobuo ;
Morita, Takayuki ;
Nishimura, Genichi ;
Sakata, Yuh ;
Takahashi, Keiichi ;
Takiuchi, Hiroya ;
Tsuruta, Osamu ;
Yamaguchi, Toshiharu ;
Yoshida, Masahiro ;
Yamaguchi, Naohiko ;
Kotake, Kenjiro ;
Sugihara, Kenichi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (01) :1-29
[19]   Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial [J].
Yamada, Yasuhide ;
Takahari, Daisuke ;
Matsumoto, Hiroshi ;
Baba, Hideo ;
Nakamura, Masato ;
Yoshida, Kazuhiro ;
Yoshida, Motoki ;
Iwamoto, Shigeyoshi ;
Shimada, Ken ;
Komatsu, Yoshito ;
Sasaki, Yasutsuna ;
Satoh, Taroh ;
Takahashi, Keiichi ;
Mishima, Hideyuki ;
Muro, Kei ;
Watanabe, Masahiko ;
Sakata, Yuh ;
Morita, Satoshi ;
Shimada, Yasuhiro ;
Sugihara, Kenichi .
LANCET ONCOLOGY, 2013, 14 (13) :1278-1286